Androgen News and Research

RSS

Discovery of new prostate cancer subtype opens the door to development of therapies

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth.

27 May 2022

Combined treatment approach proves to be beneficial for prostate cancer patients

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy - a commonly used hormone injection - plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' prostate cancer at bay for five years.

26 May 2022

The link between androgens and COVID-19

A new paper examines the association between androgens and COVID-19, as revealed by the research carried out on this topic throughout the pandemic.

20 May 2022

Researchers discover new gene that confers resistance to prostate cancer treatment

Northwestern Medicine investigators have identified a gene that confers resistance to a common prostate cancer treatment, according to a study published in Cancer Research.

13 May 2022

Targeting the mitochondrial pathway may be a potential strategy to halt prostate cancer growth

Hormone therapy is often used to treat prostate cancer that has spread to other parts of the body, but many patients develop resistance to hormone therapy, causing their disease to become more aggressive and potentially more deadly.

10 May 2022

Study uncovers new regulator of prostate cancer metastasis

A transcription factor normally associated with androgen receptor activity in prostate cancer has a newly discovered role in controlling lipid biosynthesis, according to a Northwestern Medicine study published in Nature Genetics.

10 May 2022

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

A recent study published in the journal Immunology analyzed whether sex mattered in the immune response to SARS-CoV-2.

29 Apr 2022

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

Researchers investigated whether temporary androgen suppression by degarelix improved the clinical outcomes among male patients hospitalized with COVID-19.

27 Apr 2022

CryoEM reveals never-before-seen details of the human androgen receptor

Scientists at Memorial Sloan Kettering Cancer Center (MSK) have glimpsed never-before-seen details of the human androgen receptor - the protein inside of cells that responds to male-typical hormones like testosterone.

20 Apr 2022

Breakthrough finding reveals how male sex hormones contribute to cancer-related sex bias

Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking discrepancies in incidence, progression, response to treatment and survival outcomes depending on their sex. In almost all cases, male patients have worse prognoses and outcomes.

15 Apr 2022

Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer

Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures.

13 Apr 2022

High-throughput screening assay could identify new prostate cancer drugs

A novel high-throughput screening assay is designed to identify inhibitors of the androgen receptor, which plays a critical role in the progression of prostate cancer.

6 Apr 2022

Do androgens play a role in COVID-19 severity?

Researchers assess the association between the AR polyQ polymorphism with COVID-19 severity using a large cohort of 1,136 COVID-19 male patients.

5 Apr 2022

Study reveals the oncometabolite role of progesterone in advanced prostate cancer

In a study published in Cell Reports Medicine, a group of Chinese scientists revealed the oncometabolite role of progesterone in advanced prostate cancer and strategies to eliminate its oncogenic effect as an aspect of prostate cancer treatment.

15 Mar 2022

Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients

A novel prostate cancer treatment - 225Ac-PSMA-617 radioligand therapy - has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine.

9 Mar 2022

Study uncovers new clues about the cellular processes that can lead to androgen deficiency

A laboratory study at the Miller School of Medicine's Desai Sethi Urology Institute has uncovered new clues about the cellular processes that can lead to deficiencies of androgens (male hormones) such as testosterone.

4 Mar 2022

Choice of initial treatment not related to depression, emotional well-being in prostate cancer patients

Depression and other mental health outcomes are similar for men choosing different options for initial treatment of localized prostate cancer, reports a study in The Journal of Urology, an Official Journal of the American Urological Association.

3 Mar 2022

Study finds the optimal duration of treatments for patients with high-risk prostate cancer

Patients receiving radiotherapy to treat high-risk prostate cancer also benefit from androgen deprivation therapy.

25 Feb 2022

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

A new drug, administered in combination with standard androgen-deprivation therapy and docetaxel chemotherapy, increased survival in patients with metastatic hormone-sensitive prostate cancer, according to a trial published in The New England Journal of Medicine.

23 Feb 2022

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases.

18 Feb 2022